Total trials
522
Active
90
Phase 3
0
Total enrollment
48,779
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pembrolizumab | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | — | 1 | |
| Ipilimumab | — | — | — | — | — | 1 | |
| GLP-1 receptor agonist therapy | — | — | — | — | — | 1 |
Next readouts
- 2027-04
- 2027-08
Top conditions
- Multiple Sclerosis24
- Cerebral Palsy15
- Parkinson Disease13
- Healthy9
- Anxiety9
- Periodontitis8
- Stroke6
- Gingival Recession6
Frequently asked questions about Gazi University
- How many clinical trials does Gazi University have on ClinicalTrials.gov?
- Gazi University is listed as the lead sponsor on 522 clinical trials in ClinicalTrials.gov, 90 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Gazi University's trials are in Phase 3?
- 0 of Gazi University's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Gazi University focus on?
- Gazi University's most-studied conditions on ClinicalTrials.gov are Multiple Sclerosis, Cerebral Palsy, Parkinson Disease, Healthy, Anxiety.
- When are Gazi University's next clinical trial readouts?
- Gazi University has 2 upcoming primary-completion readouts tracked here; the soonest is “GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity”, expected around 2027-04.